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Thyroid cancer is a relatively rare disease which is usually curable.
However, in some patients, it can have an aggressive course
leading even to death. In fact, thyroid cancer shows wide varia-
tions in the degree of malignancy, ranging from an almost benign
to an extremely aggressive type of cancer (Gillenwater and Weber,
1997). 
Thyroid cancer metastasizes most frequently to cervical lymph
nodes, but also to lung and bone. The occurrence of skeletal
metastases, which are often osteolytic, is associated with a high
risk of death (Marcocci et al, 1989). Moreover, bone metastases
can be responsible for pain, swelling, pathological fractures,
neurologic deficits, impaired mobility, hypercalcaemia and wors-
ening of the quality of life (Coleman and Rubens, 1985; Body,
1992; Schlumberger, 1998). 
Although the induction of the remission of the disease and the
improvement in overall survival rate remain central to cancer clin-
ical research, it is now widely accepted that relief from symptoms
and protection against skeletal complications should not be over-
looked as therapeutic goals to be achieved in cancer patients with
bone metastases. Therefore, the improvement in the quality of life
may be as important as the increase in survival rates in these
patients. 
Unfortunately, the treatment of skeletal metastases represents a
difficult challenge in thyroid cancer and clinical results are not
encouraging. In fact, the response to the therapy of bone metas-
tases through surgery (Schlumberger, 1998), radioiodine
(Marcocci et al, 1989; Maxon and Smith, 1990; Proye et al, 1992),
external irradiation (Tubiana et al, 1985), chemotherapy (Grebe
and Hay, 1995; Schlumberger, 1998) and biological therapy
(Lupoli et al, 1996; Vitale et al, 2000) is poor in thyroid cancer
patients. 
Bisphosphonates, which are potent inhibitors of osteoclastic
activity, responsible for the accelerated bone resorption in oste-
olytic metastases, represent an alternative therapeutic approach to
bone metastases due to several tumours (Cascinu et al, 1998).
Pamidronate is one of the most potent aminobisphosphonate
commercially available. The efficacy of pamidronate in malignant
bone disease is well know (Lipton et al, 1994; Cascinu et al, 1998),
although zoledronate, still under clinical investigation, seems to be
more promising. 
The aim of the present study was to evaluate the tolerability and
activity of pamidronate disodium in relation to bone pain, quality
of life, analgesic consumption and tumour mass in patients
affected by thyroid cancer with painful and progressing lytic
metastases of bone. 
MATERIAL AND METHODS 
Patient selection 
10 patients, 7 men and 3 women, ranging in age from 35 to 76
years (mean ±SD: 57.1 ±12 years; median: 58 years), with painful
bone metastases from histologically proven thyroid carcinoma (6
follicular, 2 papillary, 2 medullary), were enrolled in this study. In
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all patients initial treatment with surgery, radioiodine therapy,
external radiotherapy, chemotherapy and/or biological therapy had
been unsuccessful and they were no longer eligible for standard
antineoplastic treatments at the time of admission. 
The other criteria adopted for selecting patients to be included
in this study were: radiographic evidence of at least one osteolytic
bone lesion; absence of symptomatic heart disease; absence of
significant ascites or other third-space fluid collection; no preg-
nancy or nursing; normal liver and kidney biochemistry (total
bilirubin < 1.5 mg dl–1, aspartate aminotransferase and alanine
aminotransferase < 3 times the normal limit, prothrombin and
partial thromboplastin < 1.5 times the normal limit and creatinine
< 1.2 mg dl–1); normal value of serum calcium corrected for
albumin; absence of any skeletal complication in the previous 3
months (pathologic fracture, the need for irradiation or surgery of
bone, spinal cord compression due to vertebral collapse); a
washout period of at least 3 months before the trial from any
previous treatment with antitumour agents (radioactive iodine
therapy, external radiation therapy, chemotherapy and/or biolog-
ical therapy), bisphosphonates or other drugs known to influence
bone metabolism; an estimated life expectancy of at least 9
months. 
Treatment schedule 
Patients were treated with 90 mg pamidronate disodium (Aredia,
Novartis Farma S.p.A., Italy), administered as a 2-hour intra-
venous infusion in 500 ml of 0.9% saline. The bisphosphonate was
administered monthly for 12 consecutive cycles of therapy. 
No other anticancer treatment was allowed during the course of
the study, with the exception of TSH-suppressive therapy with 
1-thyroxine in differentiated thyroid carcinoma. This endocrine
therapy had been started at least 2 years before this trial and
remained unaltered while the therapy with pamidronate was being
followed. 
The study was approved by the Institutional Bioethical
Committee and all patients provided written informed consent. 
Evaluation of treatment tolerability 
Patients underwent clinical and biochemical examination before
entry into the study and then monthly for 12 consecutive times.
Each evaluation included complete physical examination, a
routine biochemical profile, the assessment of side effects and the
identification of any skeletal complications. All adverse events
were recorded and graded according to World Health Organization
(WHO) criteria (Miller et al, 1981). The evaluations of serum
calcium corrected for albumin and of phosphate, magnesium,
potassium, creatinine, haemoglobin and haematocrit were
performed in the first 2 weeks following the treatment. 
Evaluation of symptomatic response 
To assess symptomatic response, patients were asked to record at
baseline and quarterly the average intensity of pain during the
previous week by using a 100 mm visual analogue scale (VAS),
where 0 stood for no pain and 100 for extremely severe pain
(Huskisson scale). At the same time, patients completed the
Functional Assessment of Cancer Therapy-General questionnaire
(FACT-G, version 4). FACT-G is a multidimensional questionnaire
developed and validated in cancer patients to evaluate the
changes in the 4 main domains of the quality of life: physical well-
being (7 items), social/family well-being (7 items), emotional
well-being (6 items) and functional well-being (7 items). Patients
scored each item on a 5-point ordinal scale range ranging from 0 to
4 (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 =
very much) during the previous 7 days. The FACT-G questionnaire
is available in 24 different languages and is widely accepted in the
Italian language (Cella et al, 1993). At each time point, scores for
Eastern Cooperative Oncology Group (ECOG) performance status
according to WHO scale (Beahrs et al, 1988) and analgesic
consumption were recorded. We also calculated the Trial Outcome
Index (TOI), by adding the functional to the physical domain
score; and a pain score was obtained by adding TOI to 100-VAS.
Analgesic consumption was expressed through narcotic score.
This parameter was obtained multiplying the type of pain relief
medication administered (0 = none; 1 = analgesic; 2 = mild
narcotic; 3 = strong narcotic) by the frequency of administration (0
= none; 1 = less than daily; 2 = once a day; 3 = more frequently
than once a day) (Tong et al, 1982). 
Evaluation of tumour mass response 
The presence of bone metastases was identified by radionuclide
bone scan and assessed by plain radiography, computerized
tomography scan or magnetic resonance imaging when necessary.
In case of skeletal pain in a specific site without any evidence of
disease through radionuclide bone scan, a plain radiograph of the
painful area was made. These diagnostic procedures were
performed before starting the study and during the therapy with
pamidronate at 6 and 12 months intervals. The response of bone
lesions was assessed blindly by a radiologist according to the
following International Union Against Cancer (UICC) guidelines
for responses in breast cancer (Hayward et al, 1977). 
Complete response (CR): disappearance of all known bone
diseases, including calcification of lytic bone metastases. 
Partial response (PR): 50% or greater decrease in measurable
bone lesions or an objective improvement in evaluable, but non-
measurable bone lesions. It was not necessary for every bone
lesion to have regressed, but no bone lesion should have
progressed. 
No change (NC): bone lesions unchanged (< 50% decrease or 
< 25% increase in the size of measurable lesions). 
Progressive disease mixed (PDM): some bone lesions regress
while others progress or new bone lesions appear. 
Progressive disease failure (PDF): progression of some or all
bone lesions and/or the appearance of new bone lesions. No bone
lesion regresses. 
Disease staging of extra-skeletal metastases was performed
before the beginning of the treatment and then every 6 months
throughout the treatment by chest X-ray, neck and abdominal
ultrasound, total-body computerized tomography and/or magnetic
resonance and response according to the WHO criteria (World
Health Organization, 1979). 
Statistical analysis 
Analysis of variance with repeated measures (ANOVA) was used
to compare the scores of the following parameters during the
therapy: VAS, FACT-G, TOI, TOI + (100-VAS), performance
status and narcotic score. The most recent values were compared
to baseline using the t-test for paired data. 1588 G Vitale et al 
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All statistical analyses were performed with BMDP statistical
package (BMDP statistical software, Los Angeles, CA, USA). 
RESULTS 
Patient characteristics and treatment tolerability 
Characteristics of patients with thyroid cancer and skeletal metas-
tases are summarized in Table 1. Nine out of 10 patients completed
12 cycles of treatment with pamidronate. One patient (patient 8)
discontinued the therapy after 7 cycles because of the progression
of the disease and skeletal complications. 
The treatment was well tolerated and minor adverse events were
usually recorded only during the first cycles (Table 1). Three out of
10 patients had a transient increase in body temperature (WHO
grades I–II). Myalgia (WHO grade I) and a mild increase in
skeletal pain were observed in 1 and 2 patients, respectively.
Nausea (WHO grade I) was reported in 2 patients. All side effects
were transient, usually lasting 6–48 hours after infusion, and did
not necessitate treatment discontinuation. During the treatment,
plasma calcium and potassium decreased slightly in patient 3 and
patient 8, respectively. No significant change was observed in
haematologic, hepatic and renal parameters. Therefore, pamidronate
was safe and did not induce significant side effects. 
Symptomatic response 
Table 2 reports the variations in pain, quality of life and narcotic
score, expressed as mean ± SD, and statistical analysis during the
treatment with pamidronate. The changes in VAS scores, assessed
by analysis of variance, were statistically significant (P = 0.0052)
and the percentage decrease in mean VAS values from baseline
(Figure 1) was maximal after 3 months of therapy (–31.35%) and
minimal after 12 months (–18.92%). We also measured the quality
of life through the questionnaire FACT-G, that was well accepted
by the patients. On average, it required 5–10 minutes to be
completed and , in most cases, could be filled out by patients them-
selves with little or no assistance. We observed a statistically
significant improvement in the quality of life as measured by
FACT-G (P = 0.0059) and TOI (P = 0.0115), suggesting a clini-
cally relevant impact of pamidronate therapy in patients with bone
metastases from thyroid cancer. The maximal percentage increase
in mean FACT-G values from baseline was +16.91% after 6
months of therapy (Figure 1). When the TOI was added to the reci-
procal value of VAS score, results were also statistically signficant
(P = 0.0044). Matched t-test between baseline and one year value
was also significant for VAS, FACT-G and TOI+(100-VAS)
scores (P = 0.0157, P = 0.015 and P = 0.0303, respectively) and
this test was at the statistical significance limit for TOI (P = 0.05),
indicating that the benefit derived from the treatment was still
present after a long-term treatment.
During the trial, a decrease in narcotic score was also observed,
but this change was not statistically significant (P = 0.088) when
using analysis of variance. On the contrary, performance status,
assessed according to ECOG scale, improved at the statistical
significance limit (P = 0.051).
Tumour mass response
Partial response of bone lesions was evidenced in 2 out of 10
patients after 6 and 12 months of pamidronate therapy (patients 1
and 3). In these 2 cases a decrease greater than 50% in vertebral
and femoral lesions was observed (Table 1). In addition, 5 patients
achieved stabilization of bone lesions during the trial (patients 2, 4,
5, 6 and 10). Progression of bone lesions developed in 1 patient
after 6 months (patient 8) and in 2 patients after 12 months
(patients 7 and 9).
Table 1 Characteristics of patients, tumour mass response of skeletal metastases to pamidronate and toxicity of treatment 
Patient Sex/Age (yr) Histology Sites of skeletal Sites of extra-skeletal Tumour response Side effect (WHO grade) 
metastases metastases 
1 F/35 Follicular Spine, femur —  PR Fever (I) 
2 F/76 Papillary Spine — NC Nausea  (I) 
3 F/48 Follicular Spine, femur, tibia Liver PR ­ skeletal pain, ¯ calcium 
4 M/60 Follicular Pelvis — NC — 
5 F/46 Follicular Spine, pelvis — NC ­ skeletal pain 
6 M/56 Papillary Ribs — NC — 
7 F/54 Medullary Spine, sternum Lung  PDM Fever (II), myalgia (I) 
8 F/66 Medullary Spine, sternum, clavicle  Mediastinum PDF Fever (I), ¯ potassium 
9 F/69 Follicular Pelvis — PDF — 
10 M/61 Follicular Spine, ribs — NC Nausea (I) 
PR = partial response; NC = no change; PDM = progressive disease mixed; PDF = progressive disease failure. 
Table 2 Variations (mean ± SD) in pain, quality of life and narcotic score during the therapy with pamidronate 
Baseline 3 months 6 months 9 months 12 months P
VAS 53.9 ± 17.4 37 ± 20.7 38.5 ± 18.5 40.9 ± 15.2 43.7 ± 13.1  0.0052 
FACT-G 55 ± 16.6 62.1 ± 17.4 64.3 ± 13.7 63 ± 13.9 64 ± 12.6  0.0059 
TOI 27.2 ± 11.3 30.7 ± 12.8 32.6 ± 10.7 31.6 ± 10.4 31.1 ± 9.94  0.0115 
TOI + (100-VAS) 73.3 ± 26 94.7 ± 31.6 94.1 ± 27.4 94.1 ± 22.9  88.5 ± 19.2 0.0044 
Narcotic score 4.1 ± 2.5 3 ± 2.2  2.6 ± 1.9 3.2 ± 2.4 3.4 ± 2.4  0.088 
VAS = visual analogue scale; FACT-G = functional assessment of cancer therapy general; TOI = trial outcome index.Pamidronate in thyroid cancer 1589
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While evaluating extra-skeletal metastases, a stabilization in
hepatic lesions in patient 3 during the therapy was observed;
progression of pulmonary and mediastinal metastases occurred in
patients 7 and 8, respectively.
DISCUSSION 
Aminoderivatives, such as pamidronate, are particularly potent
bisphosphonates, that act through the induction of osteoclast apop-
tosis, probably due to the inhibition of cholesterol biosynthesis
and, consequently, to the inhibition of the isoprenylation of
proteins required for the osteoclast survival (Benford et al, 1999;
Van Beek et al, 1999). Aminobisphosphonates are commonly
administered to patients with osteolytic bone metastases caused by
several neoplasms. These agents decrease the intensity of pain and
the incidence of fractures thus improving mobility. Moreover,
several investigators have reported that X-ray showed sclerosis of
lytic bone metastases in patients treated with bisphosphonates
(Coleman et al, 1988; Morton et al, 1988; Lipton et al, 1994;
Cascinu et al, 1998). 
These data provided the rationale for our observational study to
determine the effects of the therapy with pamidronate on a selected
group of thyroid cancer patients with symptomatic and lytic
skeletal metastases. In these patients the conventional therapy
(surgery, radioactive iodine therapy, external irradiation,
chemotherapy and/or biological therapy) was unsuccessful. In the
current trial a significant decrease in bone pain was observed
during the therapy with pamidronate. In fact, in comparison to
baseline values, an average pain reduction of 31.35% was
observed after 3 months of therapy. This pain relief is the primary
goal of palliative treatment for bone metastases. We also observed
a remarkable improvement in the quality of life, assessed by
FACT-G, during the therapy. It must be noted that the effects of
pamidronate on bone pain and quality of life continued throughout
the 12 months of therapy, thus suggesting a continued effect of
pamidronate in long-term treatment. Interestingly enough, the
appearance of areas of sclerosis in lytic bone metastases induced a
partial response in 2 out of 10 patients and, in addition, in 5 out of
10 patients the disease stabilized during therapy. 
In light of previous studies, a direct antitumour effect of
pamidronate cannot be excluded. In fact, pamidronate has been
recently reported to have a cytostatic effect and to induce apop-
tosis in multiple myeloma cells. These effects cannot be solely
justified by a secondary decrease in the production of the myeloma
growth factor interleukin-6 (Shipman et al, 1997; Aparicio et al,
1998; Derenne et al, 1999). It could be assumed that the anti-
isoprenylating activity of aminobisphosphonates is responsible for
the growth inhibitory effects (Reszka et al, 1999). However, data
on thyroid tumour cells are not available yet. 
During this trial, no specific anticancer therapy was performed
with the exception of TSH-suppressive therapy with 1-thyroxine
in differentiated thyroid cancer. However, this endocrine therapy
was started before the study and was not modified during the
therapy with pamidronate. Hence, the symptomatic improvements
and the effects observed on tumour mass can potentially be attrib-
uted to pamidronate. 
Finally, intravenous pamidronate was well tolerated with
minimal and transient side effects, including low-grade fever,
myalgia, bone pain and nausea. No patient discontinued treatment
because of the toxicity of pamidronate. 
In conclusion, these preliminary data suggest that pamidronate
represents a safe, well tolerated and effective treatment for the
palliation of thyroid cancer patients with symptomatic and oste-
olytic bone metastases, inducing useful clinical benefits. The
induction of the sclerosis of bone lesions observed in a few cases
suggests that this treatment may retard disease progression and
induce clinical remission of bone metastases. However, the rarity
of thyroid cancer with osteolytic bone metastases needs larger,
multicentric and, eventually, randomized series, so as to confirm
the efficacy of pamidronate therapy in skeletal metastases from
thyroid cancer in future trials. 
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